HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Erratum (v30,p1684) All Versions of this Article: dc06-1712v1 30/4/795    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vinik, A. I. Articles by Zhang, Q. Search for Related Content PubMed PubMed Citation Articles by Vinik, A. I. Articles by Zhang, Q. Social Bookmarking                What's this?

Adding Insulin Glargine vs. Rosiglitazone: Health-Related Quality of Life Impact in Type 2 Diabetes

¹Director, Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, Norfolk, Virginia
²Manager, Health Economics, Sanofi-aventis U.S., Bridgewater, New Jersey

viniKAI{at}EVMS.EDU

ABSTRACT

Objective --- Assess health-related quality of life (HRQOL) in patients with type 2 diabetes treated with insulin glargine or rosiglitazone as add-on therapy to sulfonylurea plus metformin.

Research Design and Methods --- HRQOL was evaluated in 217 subjects uncontrolled with sulfonylurea plus metformin, enrolled in a 24-week, multicenter, randomized, open-label, parallel-group trial of add-on insulin glargine vs rosiglitazone. A 40-item, self-administered questionnaire at baseline and at weeks 2, 6, 12, 18, and 24 included the 34-item Diabetes Symptom Checklist-Revised (DSC-R), 5-item mental health scale from the Short-Form Health Survey (SF-36), and single-item health rating from the SF-36. These assessments do not specify route of therapy.

Results --- Both treatment groups showed similar improvements in glycemic control from baseline to week 24 (change in glycosylated hemoglobin A_1c [A1C], --1.66%, insulin glargine group;--1.51%, rosiglitazone group; P = 0.1446). Both groups also showed improvement in HRQOL, although subjects treated with insulin glargine experienced significantly greater improvements compared with rosiglitazone in DSC-R total symptom score (P = 0.005); total symptom distress score (P = 0.03); individual domain scores for mood symptoms (P = 0.007), ophthalmologic symptoms (P = 0.007), ophthalmologic distress (P = 0.013), and fatigue distress (P = 0.033); and SF-36 perception of general health (P = 0.047).

Conclusions --- Although addition of insulin glargine and rosiglitazone achieved comparable improvements in glycemic control, insulin glargine was associated with greater improvements in HRQOL, indicating that other factors (eg, safety profile and nonglycemic actions) may further enhance HRQOL in patients with type 2 diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Insulin Glargine vs. Rosiglitazone: Quality-of-Life Outcomes Journal Watch (General), May 3, 2007; 2007(503): 2 - 2. [Full Text]